1 / 22

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products FDA OTC A

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products FDA OTC Advisory Committee - September 20, 2002. QUESTIONS TO ADDRESS:. ARE NON-PRESCRIPTION DOSES OF OTC NSAIDs NEPHROTOXIC? IF SO, WHAT IS THE OUTCOME OF A RISK-BENEFIT ANALYSIS?.

kathie
Download Presentation

OTC NSAIDs AND NEPHROTOXICITY Juan Carlos Pelayo, M.D. On Behalf Of The Division Of Cardio-Renal Drug Products FDA OTC A

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. OTC NSAIDsANDNEPHROTOXICITYJuan Carlos Pelayo, M.D.On Behalf OfThe Division Of Cardio-Renal Drug ProductsFDA OTC Advisory Committee - September 20, 2002

  2. QUESTIONS TO ADDRESS: • ARE NON-PRESCRIPTION DOSES OF OTC NSAIDs NEPHROTOXIC? IF SO, • WHAT IS THE OUTCOME OF A RISK-BENEFIT ANALYSIS?

  3. NSAID-INDUCED NEPHROTOXICITY(PRESCRIPTION DOSES) • EDEMA • HYPERKALEMIA •  BLOOD PRESSURE •  SERUM CREATININE / ARF • PROTEINURIA / NS / INTERSTITIAL NEPHRITIS • ACUTE PAPILLARY NECROSIS • CRF

  4. AT RISK POPULATIONS • VOLUME DEPLETION • UNDERLYING KIDNEY DISEASE • HEART FAILURE • LIVER DYSFUNCTION WITH ASCITES • ELDERLY • PREGNANCY

  5. NSAID-INDUCED NEPHROTOXICITY(PRESCRIPTION DOSES) • WHAT ARE THE RATES OF OCCURRENCE OF NSAID-RELATED KIDNEY ADVERSE EVENTS FOR PRESCRIPTION DOSES?

  6. NSAID-INDUCED NEPHROTOXICITY(PRESCRIPTION DOSES) • STUDY DESIGN • PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP DESIGN • TREATMENT DURATION 18 WEEKS • 361 HEALTHY SUBJECTS WITH OSTEOARTHRITIS WERE EVALUATED PER GROUP • RENAL ADVERSE EVENTS AS REPORTED BY THE INVESTIGATORS • IBUPROFEN 2400 mg/DAILY vs.. PLACEBO

  7. EDEMA18 Weeks

  8. HYPERKALEMIA18 Weeks

  9. HYPERTENSION18 Weeks

  10.  SERUM CREATININE18 Weeks

  11. PROTEINURIA 18 Weeks

  12. NSAID-INDUCED NEPHROTOXICITY(PRESCRIPTION DOSES) • ACUTE RENAL FAILURE 0% • INTERSTITIAL NEPHRITIS 0% • ACUTE PAPILLARY NECROSIS 0%

  13. OTC NSAIDs • IBUPROFEN (1984) • Max. Dose 1200 mg/Daily (40% Prescription Dose) • NAPROXEN (1994) • Max. Dose 600 mg/Daily (40% Prescription Dose) • KETOPROFEN (1995) • Max. Dose 75 mg/Daily (25% Prescription Dose)

  14. NSAID-INDUCED NEPHROTOXICITY • DOSE LEVEL vs. NEPHROTOXICITY?

  15. ASSESSMENT OF THE NEPHROTOXIC RISK ASSOCIATED WITH OTC NSAIDs • PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED AND ADEQUATELY POWERED STUDIES COMPARING NON- vs. PRESCRIPTION DOSES OF NSAIDs • HEALTHY POPULATION • AT RISK POPULATIONS

  16. ASSESSMENT OF NEPHROTOXIC RISK ASSOCIATED WITH OTC NSAIDs • RETROSPECTIVE, UNCONTROLLED AND UNDERPOWERED STUDIES • META-ANALYSES • CASE REPORTS

  17. ASSESSMENT OF NEPHROTOXIC RISK ASSOCIATED WITH OTC NSAIDs • NATIONAL KIDNEY FOUNDATION • DATABASE OF 556 ARTICLES ON ASPIRIN, ACETOMINOPHEN, ASPIRIN-ACETOMINOPHEN COMBINATIONS, AND NSAID-RELATED NEPHROTOXICITY.

  18. NATIONAL KIDNEY FOUNDATION POSITION PAPER (1996) • RECOMMENDATION • “THERE SHOULD BE AN EXPLICIT LABEL WARNING PATIENTS TAKING OVER-THE-COUNTER NSAIDs OF THE POTENTIAL RENAL RISKS OF CONSUMING THE DRUGS.” [American Journal of Kidney Disease, Vol 27, No 1, 1996:pp 162-165.]

  19. ASSESSMENT OF NEPHROTOXIC RISK ASSOCIATED WITH OTC NSAIDs • ADVERSE EVENT REPORTING SYSTEM

  20. AERS FOR RENAL FAILURE REPORTED FOR OTC NSAIDs

  21. RISK-BENEFIT ANALYSIS • BENEFIT • THE BENEFIT OBTAINED FROM THE USE OF OTC NSAIDs ONLY RELATES TO THE RELIEF OF SYMPTOMS

  22. RISK-BENEFIT ANALYSIS • RISK • USE OF OTC NSAIDs CARRIES A NOMINAL RISK OF NEPHROTOXICITY. • HOWEVER, THERE ARE NO DATA AVAILABLE TO QUANTITATIVELY DEFINE THE RISK. THIS LACK OF INFORMATION PREVENTS US FROM REACHING A CONCLUSION ABOUT WHETHER THE RISK CHANGES WITH DOSE.

More Related